Effect of Baseline Corticosteroid Medication on Reduction in Fvc Decline with Nintedanib

Vincent Cottin,Huiping Li,Fabrizio Luppi,Florence Le Maulf,Rozsa Schlenker-Herceg,Susanne Stowasser,Roland M. Du Bois
DOI: https://doi.org/10.1183/13993003.congress-2015.oa4498
IF: 24.3
2015-01-01
European Respiratory Journal
Abstract:Background: In the two replicate, 52-week, Phase III INPULSIS® trials, patients with idiopathic pulmonary fibrosis (IPF) were randomized 3:2 to receive treatment with nintedanib 150 mg twice daily (bid) or placebo. Concomitant treatment with prednisone ≤15 mg/day, or equivalent, was permitted if the dose had been stable for ≥8 weeks prior to screening. The primary endpoint was annual rate of decline in FVC. In both trials, nintedanib significantly reduced the annual rate of FVC decline vs placebo. Aim: To assess whether corticosteroid use at baseline affected the treatment effect of nintedanib. Methods: A pre-specified analysis of patients receiving vs not receiving systemic corticosteroids at baseline was conducted using pooled data from both INPULSIS® trials. Results: At baseline, 225 patients (21.2%) were receiving corticosteroids (136 nintedanib; 89 placebo) and 836 (78.8%) were not (502 nintedanib; 334 placebo). Demographics and baseline characteristics were balanced between treatment groups within each subgroup. The difference in the adjusted annual rate of decline in FVC was 98.5 mL/year (95% CI: 24.7, 172.3) and 113.1 mL/year (95% CI: 74.5, 151.6) in patients receiving and not receiving corticosteroids at baseline, respectively. The treatment-by-subgroup interaction was not significant for the primary endpoint (p=0.9379), i.e., the treatment effect of nintedanib vs placebo was similar in both subgroups. Conclusion: In a subgroup analysis of pooled data from the INPULSIS® trials, nintedanib reduced the annual decline in lung function in patients with IPF independent of corticosteroid use at baseline.
What problem does this paper attempt to address?